16267322

Source:http://linkedlifedata.com/resource/pubmed/id/16267322

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010346, umls-concept:C0205263, umls-concept:C0677908, umls-concept:C1172734
pubmed:issue	18
pubmed:dateCreated	2005-11-3
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00032786, http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00032799
pubmed:abstractText	Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/M01RR0058
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16267322-16267329
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Integrin alpha Chains, http://linkedlifedata.com/resource/pubmed/chemical/natalizumab
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1533-4406
pubmed:author	pubmed-author:ColombelJean FrédéricJF, pubmed-author:DespainDarrinD, pubmed-author:EnnsRobertsR, pubmed-author:Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group, pubmed-author:FeaganBrian GBG, pubmed-author:GoldblumRonaldR, pubmed-author:HanauerStephen BSB, pubmed-author:HoggeGary SGS, pubmed-author:International Efficacy of Natalizumab as Active Crohn's Therapy..., pubmed-author:LawranceIan CIC, pubmed-author:PanaccioneRemoR, pubmed-author:RutgeertsPaulP, pubmed-author:SandbornWilliam JWJ, pubmed-author:SandersMartinM, pubmed-author:SchreiberStefanS, pubmed-author:TarganStephanS, pubmed-author:van DeventerSanderS
pubmed:copyrightInfo	Copyright 2005 Massachusetts Medical Society.
pubmed:issnType	Electronic
pubmed:day	3
pubmed:volume	353
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1912-25
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:16267322-Adult, pubmed-meshheading:16267322-Antibodies, Monoclonal, pubmed-meshheading:16267322-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16267322-Cell Adhesion Molecules, pubmed-meshheading:16267322-Crohn Disease, pubmed-meshheading:16267322-Double-Blind Method, pubmed-meshheading:16267322-Female, pubmed-meshheading:16267322-Humans, pubmed-meshheading:16267322-Immunosuppressive Agents, pubmed-meshheading:16267322-Integrin alpha Chains, pubmed-meshheading:16267322-JC Virus, pubmed-meshheading:16267322-Leukoencephalopathy, Progressive Multifocal, pubmed-meshheading:16267322-Male, pubmed-meshheading:16267322-Remission Induction, pubmed-meshheading:16267322-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	Natalizumab induction and maintenance therapy for Crohn's disease.
pubmed:affiliation	Mayo Clinic, Rochester, Minn 55905, USA. sandborn.william@mayo.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Research Support, N.I.H., Extramural